Top

International Journal of Clinical Oncology

Published in:

01-10-2012 | Original Article

Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy

Authors: Tatsuo Gondo, Jun Nakashima, Choichiro Ozu, Yoshio Ohno, Yutaka Horiguchi, Kazunori Namiki, Kunihiko Yoshioka, Makoto Ohori, Tadashi Hatano, Masaaki Tachibana

Published in: International Journal of Clinical Oncology | Issue 5/2012

Abstract

Background

The aim of this study was to investigate prognostic factors and develop a prognostic factor-based risk stratification model for disease-specific survival (DSS) in a radical cystectomy (RC) series.

Methods

The patient cohort comprised 194 consecutive patients with bladder cancer treated with RC. Univariate and multivariate Cox proportional hazard model analyses were performed to identify significant prognostic factors for DSS. A risk stratification model was developed based on the relative risks (RRs) of DSS.

Results

Median follow-up period was 26.8 months. The 1-, 3-, and 5-year DSS were 88.0, 74.0, and 64.9%, respectively. In the univariate analysis, pathological T (pT) (≥pT2), lymphovascular invasion (LVI), non-urothelial carcinoma component, surgical margin (SM), and lymph node metastases (pN) were significantly associated with poor prognosis. In the multivariate analysis, pT (≥pT2), LVI, and SM were independent factors for predicting poor prognosis. Based on these results, patients were stratified into three risk groups: low (RR = 1.00–3.626), intermediate (5.860–9.826), and high (21.24). The 1-, 3-, and 5-year survival rates were 96.9, 85.1, and 85.1% in the low-risk group, 83.0, 63.4, and 43.8% in the intermediate group, and 51.0, 19.4, and 19.4% in the high-risk group, respectively. The differences among these groups were significant.

Conclusions

In our RC series, pT (≥pT2), LVI, and SM were independent prognostic factors. This information may be useful to identify patients with poor prognosis, who might be good candidates for innovative treatment.

Ennis R, Petrylak D, Singh P et al (2000) The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J Urol 163:1413–1418PubMedCrossRef

Stein J, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed

Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19:4005–4013PubMed

Dalbagni G, Genega E, Hashibe M et al (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165:1111–1116PubMedCrossRef

Thrasher J, Frazier H, Robertson J et al (1994) Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73:1708–1715PubMedCrossRef

Bassi P, Ferrante G, Piazza N et al (1999) Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161:1494–1497PubMedCrossRef

Shariat S, Karakiewicz P, Palapattu G et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422 (discussion 2422)PubMedCrossRef

Abdel-Latif M, Abol-Enein H, El-Baz M et al (2004) Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172:85–89PubMedCrossRef

Bolenz C, Herrmann E, Bastian P et al (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 106(4):493–499

10.

Lotan Y, Gupta A, Shariat S et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539PubMedCrossRef

11.

Karakiewicz P, Shariat S, Palapattu G et al (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176:1354–1361 (discussion 1361–1362)PubMedCrossRef

12.

Shariat S, Karakiewicz P, Palapattu G et al (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12:6663–6676PubMedCrossRef

13.

Yang M, Yen C, Chen P et al (2002) Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan. Urology 59:232–238 (discussion 238–239)PubMedCrossRef

14.

Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 108:687–692. doi:10.1111/j.1464-410X.2010.09902.x

15.

Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185:1216–1221PubMedCrossRef

16.

Hasui Y, Nishi S, Kitada S et al (1992) The prognostic significance of vascular invasion in upper urinary tract transitional cell carcinoma. J Urol 148:1783–1785PubMed

17.

Kikuchi E, Horiguchi Y, Nakashima J et al (2005) Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol 174:2120–2123PubMedCrossRef

18.

Slaton J, Swanson D, Grossman H et al (1999) A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 162:710–714PubMedCrossRef

19.

Borden LJ, Clark P, Hall M (2003) Bladder cancer. Curr Opin Oncol 15:227–233PubMedCrossRef

20.

Kikuchi E, Margulis V, Karakiewicz P et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618PubMedCrossRef

21.

Leissner J, Koeppen C, Wolf H (2003) Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 169:955–960PubMedCrossRef

22.

Manoharan M, Katkoori D, Kishore TA et al (2010) Lymphovascular invasion in radical cystectomy specimen: is it an independent prognostic factor in patients without lymph node metastases? World J Urol 28:233–237PubMedCrossRef

23.

Palmieri F, Brunocilla E, Bertaccini A et al (2010) Prognostic value of lymphovascular invasion in bladder cancer in patients treated with radical cystectomy. Anticancer Res 30:2973–2976PubMed

24.

Quek M, Stein J, Nichols P et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103–106PubMedCrossRef

25.

Canter D, Guzzo T, Resnick M et al (2008) The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int 102:952–957PubMedCrossRef

26.

Manoharan M, Katkoori D, Kishore T et al (2010) Lymphovascular invasion in radical cystectomy specimen: is it an independent prognostic factor in patients without lymph node metastases? World J Urol 28:233–237PubMedCrossRef

27.

Hadjizacharia P, Stein J, Cai J et al (2009) The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol 27:33–38PubMedCrossRef

28.

Novara G, Svatek R, Karakiewicz P et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183:2165–2170PubMedCrossRef

29.

Antunes A, Nesrallah L, Dall’Oglio M et al (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33:339–345 (discussion 346)PubMedCrossRef

30.

Ghoneim MA, Abdel-Latif M, el-Mekresh M et al (2008) Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 180:121–127PubMedCrossRef

Title: Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy
Authors: Tatsuo Gondo
Jun Nakashima
Choichiro Ozu
Yoshio Ohno
Yutaka Horiguchi
Kazunori Namiki
Kunihiko Yoshioka
Makoto Ohori
Tadashi Hatano
Masaaki Tachibana
Publication date: 01-10-2012
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0310-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy

Molecular-targeted therapies for ovarian cancer: prospects for the future

Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer

Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy

Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases

Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer